

<u>Line of Business</u>	Reported 2015 Revenue				
	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>TOTAL</u>
U.S. OmniPod	\$ 39.2	\$ 44.7	\$ 50.0	\$ 52.9	\$ 186.8
Int'l OmniPod	\$ 3.7	\$ 7.7	\$ 13.5	\$ 15.4	\$ 40.3
Drug Delivery	\$ 4.7	\$ 7.5	\$ 7.1	\$ 14.7	\$ 34.0
Neighborhood	\$ 13.6	\$ 15.7	\$ 16.7	\$ 17.1	\$ 63.1
TOTAL	\$ 61.2	\$ 75.6	\$ 87.3	\$ 100.1	\$ 324.2

Divestiture of Neighborhood Diabetes

On February 12, 2016, Insulet sold Neighborhood Diabetes to Liberty Medical LLC. Insulet's 2015 reported results include Neighborhood Diabetes. However, following the divestiture, the Neighborhood results will no longer be included in our continuing operations and our forward-looking guidance reflects this change. To assist you with your modeling and for clearer year-over-year comparison, we have provided unaudited pro forma 2015 financial statements in our year-end 2015 earnings release, which exclude the Neighborhood Diabetes business as if it were divested on January 1st of 2015. In addition, below is a schedule of the unaudited pro forma revenue for each quarter of 2015 reflecting this divestiture.

<u>Line of Business</u>	PRO FORMA 2015 Revenue (reflects divestiture of Neighborhood Diabetes as if it occurred on Jan. 1, 2015)				
	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>TOTAL</u>
U.S. OmniPod (1)	\$ 39.7	\$ 45.4	\$ 50.8	\$ 53.7	\$ 189.6
Int'l OmniPod	\$ 3.7	\$ 7.7	\$ 13.5	\$ 15.4	\$ 40.3
Drug Delivery	\$ 4.7	\$ 7.5	\$ 7.1	\$ 14.7	\$ 34.0
TOTAL (2)	\$ 48.1	\$ 60.6	\$ 71.4	\$ 83.8	\$ 263.9

(1)- U.S. OmniPod - The differences between the reported revenue results for U.S. OmniPod and the adjustments represent the portion of OmniPod sales transacted through Neighborhood Diabetes which remain with Insulet's ongoing operations. These amounts were previously reported in the Neighborhood Diabetes revenue results. See the reconciliation below.

(2)- Total Company Pro Forma Revenue includes adjustments for revenue no longer expected to be incurred due to the divestiture of the Neighborhood Diabetes supplies business in February 2016. The differences between the reported revenue results for Neighborhood Diabetes and the adjustments represent the portion of OmniPod sales transacted through Neighborhood Diabetes which remain with Insulet's ongoing operations. See the reconciliation below.

Pro Forma 2015 Revenue Reconciliation					
	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>TOTAL</u>
U.S. OmniPod - As Reported	\$ 39.2	\$ 44.7	\$ 50.0	\$ 52.9	\$ 186.8
Adjustments	\$ 0.5	\$ 0.7	\$ 0.8	\$ 0.8	\$ 2.8
U.S. OmniPod - Pro Forma (1)	<u>\$ 39.7</u>	<u>\$ 45.4</u>	<u>\$ 50.8</u>	<u>\$ 53.7</u>	<u>\$ 189.6</u>
Total Company - As Reported	\$ 61.2	\$ 75.6	\$ 87.3	\$ 100.1	\$ 324.2
Adjustments	\$ (13.1)	\$ (15.0)	\$ (15.9)	\$ (16.3)	\$ (60.3)
Total Company - Pro Forma (2)	<u>\$ 48.1</u>	<u>\$ 60.6</u>	<u>\$ 71.4</u>	<u>\$ 83.8</u>	<u>\$ 263.9</u>